[{"id":"30039935-dcb8-4bf7-a489-908bf7235f71","acronym":"LUMINOSITY","url":"https://clinicaltrials.gov/study/NCT03539536","created_at":"2021-01-18T17:26:22.732Z","updated_at":"2024-07-02T16:35:22.832Z","phase":"Phase 2","brief_title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03539536 - LUMINOSITY","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • MET overexpression • MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-01-19"},{"id":"88937094-cd92-4d3c-b628-9e0e2ffc12f1","acronym":"M14-237","url":"https://clinicaltrials.gov/study/NCT02099058","created_at":"2021-01-17T17:35:29.259Z","updated_at":"2024-07-02T16:35:42.807Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02099058 - M14-237","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tagrisso (osimertinib) • erlotinib • Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 04/24/2024","primary_completion_date":" 04/24/2024","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2023-07-17"},{"id":"37e87c1e-114e-4f1c-b7dd-21fefdb4dfe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472016","created_at":"2021-01-18T06:08:12.319Z","updated_at":"2024-07-02T16:37:16.171Z","phase":"Phase 1","brief_title":"Study of ABT-700 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01472016","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • erlotinib • docetaxel • 5-fluorouracil • irinotecan • leucovorin calcium • telisotuzumab (h224G11)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 10/06/2011","start_date":" 10/06/2011","primary_txt":" Primary completion: 04/27/2017","primary_completion_date":" 04/27/2017","study_txt":" Completion: 04/27/2017","study_completion_date":" 04/27/2017","last_update_posted":"2017-11-21"}]